Transgene, A Biotech Company That Designs And Develops Virus-Based Immunotherapies For The Treatment Of Cancer, And Nec Corporation, A Leader In It, Network And Ai Technologies, Announce Positive Preliminary Immunogenicity And Clinical Data On Tg4050, Their Jointly Developed Individualized Neoantigen Cancer Vaccine.Tg4050 Is The First Candidate Based On Transgene
